TLDR
- SLS hit a fresh 52-week high of $11.06, trading up over 17% Thursday
- An 8-K filing revealed amended executive employment agreements, including lump-sum change-of-control payments and immediate equity vesting — moves investors often read as M&A prep
- The Phase 3 REGAL trial for AML immunotherapy Galinpepimut-S is at 78 of 80 required survival events, putting a readout very close
- Q1 adjusted loss per share came in at -$0.05, better than the -$0.07 analyst estimate; cash stands at $107.1 million
- RSI sits at 72.67, putting the stock in overbought territory
SELLAS Life Sciences Group (SLS) had a big Thursday. The stock surged more than 17% intraday, hitting a fresh 52-week high of $11.06 and trading around $10.78 at time of publication. That follows a 396% run over the past year.
SELLAS Life Sciences Group, Inc., SLS
The catalyst this time was an 8-K filing.
SELLAS amended executive employment and severance agreements for CEO Dr. Angelos Stergiou and CFO John Burns. The updated terms include lump-sum change-of-control payments and mandatory immediate equity vesting on qualifying termination.
In biotech, that kind of executive contract restructuring tends to get investors’ attention fast. It’s a setup that traders commonly associate with an incoming acquisition, merger, or strategic partnership.
The company has not commented on any deal.
Phase 3 Trial Nearing the Finish Line
The contract changes come at a particularly sensitive moment for SELLAS. Its pivotal Phase 3 REGAL trial — testing Galinpepimut-S (GPS), a WT1-targeting peptide immunotherapy for acute myeloid leukemia — is sitting at 78 of the 80 survival events required to unblind final data.
The company remains blinded to the outcome. But with just two events left before the data lock, a readout could come any day. That alone has kept SLS on traders’ watchlists.
The pipeline also includes GFH009, a selective CDK9 inhibitor, though GPS is clearly the near-term focus.
Financials and Technical Setup
On the numbers side, SELLAS posted a Q1 adjusted loss per share of -$0.05, beating the -$0.07 analyst estimate. Cash and equivalents stood at $107.1 million as of March 31, boosted by approximately $28.7 million raised from warrant exercises in April and May.
Technically, the stock is extended. SLS is trading roughly 27% above its 20-day moving average and about 164% above its 200-day moving average. The RSI reads 72.67 — overbought by standard measures.
Key resistance sits at $10.65. The former 52-week high of $9.51 now acts as the first support level on any pullback.
With a beta of 2.53, volatility is part of the deal here. There are 196,632,574 common shares outstanding, and the market cap sits around $1.76 billion.
SLS was up 17.56% at $10.78 at time of publication Thursday.
🚨 Our JUNE Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for June, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
